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Hypersensitivity to mGluR5 and ERK1/2 leads to excessive
protein synthesis in the hippocampus of a mouse model of
fragile X syndrome
Emily K. Osterweil, Dilja D. Krueger, Kimberly Reinhold, and Mark F. Bear
Howard Hughes Medical Institute, Picower Institute for learning and Memory, Department of Brain
and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA
Abstract
Fragile X syndrome (FXS) is caused by loss of the FMR1 gene product FMRP, a repressor of
mRNA translation. According to the mGluR theory of FXS, excessive protein synthesis
downstream of metabotropic glutamate receptor 5 (mGluR5) activation causes the synaptic
pathophysiology that underlies multiple aspects of fragile X syndrome (FXS). Here, we utilize an
in vitro assay of protein synthesis in the hippocampus of male Fmr1 KO mice to explore the
molecular mechanisms involved in this core biochemical phenotype under conditions where
aberrant synaptic physiology has been observed. We find that elevated basal protein synthesis in
Fmr1 KO mice is selectively reduced to wild type (WT) levels by acute inhibition of mGluR5 or
ERK1/2, but not by inhibition of mTOR. The mGluR5-ERK1/2 pathway is not constitutively
overactive in the Fmr1 KO, however, suggesting that mRNA translation is hypersensitive to basal
ERK1/2 activation in the absence of FMRP. We find that hypersensitivity to ERK1/2 pathway
activation also contributes to audiogenic seizure susceptibility in the Fmr1 KO. These results
suggest that the ERK1/2 pathway, and other neurotransmitter systems that stimulate protein
synthesis via ERK1/2, represent additional therapeutic targets for FXS.
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Introduction
Fragile X syndrome (FXS) is caused by the loss of the FMR1 gene product FMRP (Verkerk
et al., 1991). Converging lines of evidence suggest that FMRP represses mRNA translation
in neurons and that cerebral protein synthesis is elevated in the absence of FMRP
(Laggerbauer et al., 2001; Li et al., 2001; Huber et al., 2002; Aschrafi et al., 2005; Qin et al.,
2005; Dolen et al., 2007; Bolduc et al., 2008). Group 1 (Gp1) metabotropic glutamate
receptors (mGluR1 and mGluR5) stimulate mRNA translation at synapses (Weiler and
Greenough, 1993; Weiler et al., 1997) and many lasting physiological consequences of Gp1
mGluR activation require rapid synaptic protein synthesis (Merlin et al., 1998; Huber et al.,
2000; Raymond et al., 2000; Karachot et al., 2001; Vanderklish and Edelman, 2002; Banko
et al., 2006). Based initially on the finding that mGluR-dependent long-term synaptic
depression (mGluR-LTD) is exaggerated in the hippocampus of Fmr1 knockout (KO) mice
(Huber et al., 2002), the proposal was made that many of the symptoms of FXS might
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plausibly be explained by excessive protein synthesis downstream of Gp1 mGluR activation
(Bear et al., 2004). The prediction that multiple aspects of fragile X can be corrected by
reducing or inhibiting mGluR5 has been confirmed in numerous studies in several species
(reviewed by Dolen and Bear, 2008).
Although it is now clear that mGluR5 participates in the pathogenesis of FXS, at least in
animal models, it is still poorly understood how Gp1 mGluRs trigger protein synthesis and
how this process is altered in the absence of FMRP to disrupt synaptic function. Several
studies have examined this issue in the hippocampus and cortex, but no clear consensus has
emerged (Weiler et al., 2004; Hou et al., 2006; Muddashetty et al., 2007; Kim et al., 2008;
Park et al., 2008; Ronesi and Huber, 2008; Sharma et al., 2010). One source of confusion
may be that proxy measures of protein synthesis, such as mGluR-LTD or phosphorylation of
signaling molecules, have been used in intact hippocampal slice preparations, whereas
metabolic labeling experiments have been performed in synaptoneurosome preparations of
cortex that are not easily related to altered hippocampal synaptic plasticity.
In the current study, we reexamine the question of how protein synthesis is elevated in the
Fmr1 KO using a metabolic labeling approach in hippocampal slices maintained under the
same conditions that revealed altered mGluR-dependent synaptic plasticity in previous
studies from our laboratory (Huber et al., 2002; Auerbach and Bear, 2010). A strong
rationale for taking this approach is that slice has been shown to accurately reproduce the in
vivo phenotype of elevated basal protein synthesis in the Fmr1 KO hippocampus (cf. Qin et
al., 2005; Dolen et al., 2007). Further, besides reproducing this core biochemical phenotype,
the slice has the advantage that it enables pharmacological and biochemical access that is
not possible in vivo. Our data suggest that elevated protein synthesis in the Fmr1 KO is due
to saturation of mRNA translation downstream of the MAP kinase ERK1/2 which is basally
activated by mGluR5.
Materials and Methods
Mice
Fmr1 KO (Jackson Labs) and wild type littermates were kept on the C57Bl/6J background,
group housed, and maintained in a 12:12 h light:dark cycle. All animals were treated in
accordance with NIH and MIT guidelines. All experiments were performed blind to
genotype. On each day of slice experimentation, 4 animals from each genotype were
sacrificed in an interleaved fashion and slices were prepared as rapidly as possible (≤ 5 min)
as described below. This procedure yielded yoked, same-day controls for genotype and drug
treatments.
Drugs
(R,S)-3,5-Dihydroxyphenylglycine (DHPG), 2-Methyl-6-(phenylethynyl)pyridine
hydrochloride (MPEP), 1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene
(U0126), actinomycin D (ActD), and a-[Amino[(4-aminophenyl)thio]methylene]-2-
(trifluoromet hyl)benzeneacetonitrile (SL 327) were obtained from Tocris Bioscience.
DHPG and MPEP stocks were freshly prepared in ddH2O on the day of the experiment.
ActD stock was prepared in ACSF + 0.5% DMSO and kept at −20°C. Anti-TrkB (R&D
Systems), BDNF (Peprotech), insulin (Sigma), rapamycin (EMD Biosciences),
cycloheximide (EMD Biosciences), U0126, and SL 327 were reconstituted according to
manufacturer’s instructions and either used immediately or stored at −20°C. For all slice
experiments, the final concentration of DMSO was less than 0.1%.
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Metabolic labeling
Juvenile (P25–P30) male littermate WT and Fmr1 KO mice were given an overdose of
Nembutal, and the hippocampus rapidly dissected into ice-cold artificial cerebral spinal fluid
(ACSF) (in mM: NaCl: 124, KCl: 3, NaH2PO4: 1.25, NaHCO3: 26, dextrose: 10, MgCl2: 1,
CaCl2: 2, saturated with 95% O2 and 5% CO2). Slices (500 µm thick) were prepared using a
Stoelting Tissue Slicer, and transferred into 32.5°C ACSF (saturated with 95% O2 and 5%
CO2) within 5 min. Unless indicated otherwise, slices were incubated in ACSF undisturbed
for 3.5–4 h to allow for recovery of protein synthesis (Sajikumar et al., 2005). 25 µM ActD
was then added to the recovery chamber for 30 min to inhibit transcription. For DHPG (100
µM) and whole-slice MPEP (50 µM) experiments, slices were incubated in 10 µCi/ml 35S-
Met/Cys (express protein labeling mix, Perkin Elmer) ± drug for 5 min, and transferred to
fresh ACSF with 10 µCi/ml 35S-Met/Cys for another 25 min to measure protein synthesis.
For cycloheximide (60 µM; performed in WT), CA1 MPEP (10 µM), U0126 (5 µM), and
rapamycin (20 nM) experiments, slices were incubated ± drug during ActD exposure (30
min), and transferred to fresh ACSF with 10 µCi/ml 35S-Met/Cys ± drug for another 30 min.
For TrkB activation experiments, slices were incubated ± 1 µg/ml anti-TrkB for 30 min, then
25 µM ActD ± 1 µg/ml anti-TrkB for 30 min, and protein synthesis measured with 10 µCi/
ml 35S-Met/Cys ± 1 µg/ml anti-TrkB for 1 h. After labeling, slices were either snap frozen in
liquid nitrogen or processed immediately.
With the exception of CA1 MPEP experiments, slices were homogenized in ice-cold
homogenization buffer (10 mM HEPES pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% Triton
X-100, protease inhibitors (cocktail III, EMD Biosciences), and phosphatase inhibitors
(cocktails I + II, EMD Biosciences)), and incubated in trichloroacetic acid (TCA; 10% final)
for 10 min on ice to precipitate radiolabeled proteins. Samples were then spun at 21,000×g
for 10 min, and the pellet washed with ice-cold ddH2O and resuspended in 1 N NaOH until
dissolved. After adjustment to a neutral pH with HCl, triplicate aliquots of each sample were
added to scintillation cocktail (HiSafe II, Perkin Elmer) and read with a scintillation counter,
and also subjected to a protein concentration assay (Bio-Rad). Averaged triplicate counts per
minute (CPM) values were divided by protein concentrations, resulting in CPM per µg
protein. To control for daily variation in incorporation rate, the values obtained on each day
were normalized to the 35S-Met/Cys ACSF used for incubation, and the average
incorporation of all slices analyzed in that experiment, as described by Lipton and Raley-
Susman (1999).
For CA1-MPEP experiments, slices were briefly thawed and CA1 regions were dissected.
To obtain autoradiographs, aliquots of homogenized CA1 were taken prior to TCA
precipitation and boiled in Laemmli sample buffer. Samples were then resolved on SDS
PAGE gels, transferred to nitrocellulose, and stained for total protein (Memcode staining kit,
Pierce). Blots were exposed to a phosphorimager screen for 24–72 hours, and the screen
read with a phosphorimager (Fujifilm). To quantify autoradiographs and Memcode-stained
blots, a line-scan of each lane was measured and quantified using the gel analyzer tool in
Image J. Protein synthesis was calculated by normalizing data from autoradiographs to
Memcode staining data obtained from the same lanes.
Acute stimulation
Slices were prepared and allowed to recover as for metabolic labeling, incubated in 100 µM
DHPG for exactly 5 min or 1 µM insulin for 10 min, then snap frozen in liquid nitrogen.
Frozen slices were either immediately homogenized in Laemmli sample buffer containing
phosphatase inhibitors, or briefly thawed and microdissected in homogenization buffer with
protease and phosphatase inhibitors (minus detergent). Microdissected regions were
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homogenized in sample buffer containing phosphatase inhibitors immediately following
dissection.
Synaptoneurosomes
Synaptoneurosomes were isolated from sets of 4 slices essentially as described previously
(Chen and Bear, 2007). Slices were homogenized on ice using 2 ml glass dounces
(Wheaton), passed through 2 × 105 µm meshes, followed by 1 × 5 µm mesh, and the
resulting samples spun at 1,000 × g for 10 min at 4°C. Pellets were washed, spun at 1,000 ×
g, and processed for SDS PAGE.
Immunoblotting
Samples were boiled in Laemmli sample buffer, resolved on SDS PAGE gels, transferred to
nitrocellulose, and stained for total protein. Immunoblotting was performed with the
following primary antibodies: from Cell Signaling Technology: p-ERK1/2 (Thr202/Tyr204),
ERK1/2, p-p38 (Thr180/Tyr182), p38, p-Akt (Ser473), p-mTOR (Ser2448), mTOR, p-
PTEN (Ser380/Thr382/383), PTEN, p-p70S6K (Thr389), p70S6K, p-S6 (Ser235/236), S6 p-
Trk (Tyr490), and GAPDH; other: TrkB (BD Biosciences), and alpha-CaMKII (Sigma).
After incubation in primary antibody overnight at 4°C, immunoblots were either incubated
with fluorophore-conjugated secondary antibodies and imaged with the Odyssey imaging
system (LiCor Biosciences), or incubated with HRP-conjugated secondary antibodies (GE
Healthcare), developed with ECL plus (GE Healthcare) and exposed to film. Densitometry
was performed on scanned blot films or LiCor images using Quantity One software (Bio-
Rad). Data were expressed as the value of the phosphorylation signal divided by the value of
the total protein signal in the same lane. To correct for blot-to-blot variance, each signal was
normalized to the average signal of all lanes on the same blot. All gels were loaded and
analyzed blind to genotype and treatment.
Fresh dissections
WT and Fmr1 KO (P25–32) male littermates were sacrificed by rapid decapitation, and
hippocampi rapidly dissected into ice-cold homogenization buffer. Tissue was homogenized
on ice using 2 ml glass dounces, and processed for SDS PAGE.
Immunoprecipitation
Hippocampal slices (5–8 per animal) were prepared as described above from WT and Fmr1
KO mice and metabolically labeled with 50 µCi/ml 35S-Met/Cys for 1 h in order to ensure
visualization of individual target proteins. Immunoprecipitation (IP) experiments were
performed on yoked WT and Fmr1 KO slices essentially as described in Osterweil et al.
(2005) and Kundel et al. (2009). Briefly, slices were homogenized in ice-cold
homogenization buffer with 200 mM NaCl, spun at 2,000 × g for 5 min, and the supernatant
adjusted to 400 mM NaCl. Samples were then spun at 16,000 × g for 30 min, pre-cleared
with 1/10 volume protein-A-sepharose (GE Healthcare) for 1 hour at 4°C, and incubated 10
µg/ml non-immune mouse IgG (Santa Cruz), mouse anti-GAPDH (Millipore), or mouse
anti-alpha-CaMKII (Millipore) overnight at 4°C. Samples were then incubated with 1/10
volume protein-A-sepharose for 2 h at 4°C, and the IPs washed 5 × 1 ml homogenization
buffer with 400 mM NaCl. IPs were resuspended in an equal volume Laemmli sample
buffer, resolved on SDS PAGE gels, transferred to nitrocellulose, and exposed to a
phosphorimager screen for 2–3 weeks. The same membranes were then immunoblotted for
alpha-CaMKII and GAPDH. For each sample, the ratio of 35S-incorporated : total was
calculated by dividing the density of the band seen by autoradiography to the density of
band seen by immunoblot (in the same lane). Experiments were performed and analyzed
blind to genotype.
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TrkB stimulation
Hippocampal neurons were prepared from E18 rat embryos as described (Krueger and
Nairn, 2007), and cultured for 21 days. 30 min prior to stimulation, the medium was
removed and replaced with 0.75 ml medium (50% conditioned, 50% fresh) to control for
volume. TrkB stimulation was performed with a 15 min incubation of vehicle or 1 µg/ml
anti-TrkB, followed by application of vehicle or 100 ng/ml BDNF for 5 min. Plates were
then washed with ice-cold PBS, and cells lysed in buffer containing 50 mM Tris, pH 7.4, 1
mM EDTA, 1 mM EGTA, 1% SDS, protease inhibitors and phosphatase inhibitors. Whole-
cell lysates were processed for SDS PAGE and immunoblotted.
Audiogenic seizures (AGS)
Experiments were performed essentially as described previously (Dolen et al., 2007). Male
WT and Fmr1 KO littermates (P18–22) were injected intraperitoneally (i.p.) with SL 327
(100 mg/kg; dose based on Zhong et al., 2009), rapamycin (6 mg/kg; dose based on
Ehninger et al., 2008 and Meikle et al., 2008) or an equal volume of vehicle (50% DMSO in
ddH2O for SL 327 experiments; 100% DMSO for rapamycin experiments), and returned to
their home cage for 1 hour. Each testing session contained at least one set of vehicle-treated
controls from each genotype. Mice were then transferred to a transparent plastic test
chamber and, after at least 1 minute of habituation, exposed to an alarm (modified personal
alarm, 125 dB Radioshack model 49–1010 or 130 dB Samfe model SWPDAL-130, powered
from a DC converter) for 2 minutes. For each group, incidence of the following stages of
AGS was calculated: wild running, clonic seizure, tonic seizure, and death. All mice were
injected and scored blind to genotype.
Statistics
For AGS experiments, significance was determined using two-tailed Fisher’s exact test
(appropriate for analyzing nominal data sets). For recovery time-course experiments,
significance was determined using repeated-measures ANOVA, followed by post hoc two-
tailed unpaired Student’s t-tests. For all other experiments, outliers (± 2 standard deviations
from the mean) were removed, and significance between more than two groups was
determined by two-way repeated measures mixed model ANOVA. If significant effects
were found by ANOVA, post hoc analyses were performed to compare individual groups
using two-tailed paired Student’s t-tests. For data sets that contained only two groups,
significance was determined by two-tailed paired Student’s t-tests.
Results
Basal protein synthesis is elevated in Fmr1 KO hippocampus
The molecular mechanisms underlying dysfunctional protein synthesis in the Fmr1 KO are
largely unknown. To explore this question, we employed an in vitro assay designed to
measure protein synthesis in acute hippocampal slices. In order to directly relate our
observations to the aberrant physiology seen in the Fmr1 KO, we examined slices isolated
from P (postnatal day) 25–30 dorsal hippocampus, as this is when and where exaggerated
mGluR- and protein synthesis-dependent LTD is observed (Huber et al., 2002). Slices were
prepared from dorsal hippocampus, and immediately transferred to 32.5°C ACSF (see
Materials and Methods). These slices were then exposed to actinomycin D (ActD, 25 µM)
for 30 minutes to prevent new transcription, and protein synthesis was measured over 30
minutes via incorporation of a 35S-labeled methionine/cysteine mix (10 µCi/ml 35S-Met/
Cys). To verify that our measurements accurately reflect global protein synthesis, slices
were incubated ± 60 µM cycloheximide for 30 minutes, and protein synthesis measured ± 60
µM cycloheximide for an additional 30 minutes. This experiment confirmed that exposure to
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cycloheximide, a potent inhibitor of mRNA translation, completely eliminates 35S-Met/Cys
incorporation (Figure S1).
A number of previous studies suggest that a long (> 2–4 hour) post-slicing recovery period
is necessary to achieve stability in metabolic function (i.e., ATP and creatine levels
(Whittingham et al., 1984), signaling cascades (Ho et al., 2004), dendritic spine density
(Kirov et al., 1999), and protein synthesis-dependent synaptic plasticity (Huber et al., 2001;
Sajikumar et al., 2005). We confirmed and extended this conclusion using our assay of basal
protein synthesis in hippocampal slices. We found that optimal and stable protein synthesis
recovers 4–6 hours after preparing slices (protein synthesis expressed as % ± SEM of 4 hr
value: 0.5 h 76 ± 7%; 1 h 72 ± 8%; 2 h 88 ± 9%; 4 h 100 ± 8%; 6 h 99 ± 8%; ANOVA time
p < 0.05; n = 10; Figure 1A). This observation is consistent with electrophysiological
measurements of optimal protein synthesis-dependent synaptic plasticity in the hippocampus
(Sajikumar et al., 2005), including optimal mGluR-LTD (Huber et al., 2001). Therefore for
all experiments reported here, the hippocampus was allowed to recover for at least 4 hours
following slicing.
To examine whether protein synthesis is elevated in Fmr1 KO hippocampus under
conditions where exaggerated mGluR-LTD is observed, we performed metabolic labeling on
juvenile, dorsal Fmr1 KO slices. Our results reveal a significant elevation of basal protein
synthesis in Fmr1 KO hippocampus as compared to wild type (WT) controls (WT 100 ± 3%,
KO 119 ± 5%; t-test p < 0.02; n = 13; Figure 1B). The magnitude of this increase in protein
synthesis is in quantitative agreement with in vivo measurements (Qin et al., 2005), and with
our previous results in adult, ventral hippocampus (Dolen et al., 2007).
Autoradiographs of Fmr1 KO versus WT slices show an increased 35S-Met/Cys
incorporation into proteins of multiple molecular weights, which supports the proposal that
FMRP functions as a rather general repressor of translation (Figure 1B) (Laggerbauer et al.,
2001; Li et al., 2001; Mazroui et al., 2002; Aschrafi et al., 2005). To confirm that our
measurement of increased total protein synthesis reflects de-repression of FMRP-regulated
translation, we performed immunoprecipitation (IP) experiments to isolate newly made
alpha-Ca2+/calmodulin-dependent kinase kinase II (alpha-CaMKII), a validated target
mRNA for FMRP (Brown et al., 2001; Zalfa et al., 2003; Ferrari et al., 2007; Muddashetty
et al., 2007). Alpha-CaMKII was immunoprecipitated from WT and Fmr1 KO slices that
had been metabolically labeled with 50 µCi/ml 35S-Met/Cys for 1 hour (see Materials and
Methods). To ensure the efficacy of our IP experiments, we quantified the amount of alpha-
CaMKII (assessed by immunoblot) observed in anti-alpha-CaMKII IPs versus IgG IPs from
the same lysates (Figure S2A). Our results confirm that alpha-CaMKII is significantly
enriched in the anti-alpha-CaMKII IPs from both WT and Fmr1 KO slices (WT IgG 100 ±
12%, WT CaMK 600 ± 73%, KO IgG 70 ± 25%, KO CaMK 544 ± 45%; t-test WT IgG vs.
CaMK *p < 0.002, t-test KO IgG vs. CaMK *p < 0.0001; n = 6; Figure S2A). To quantify
newly translated protein, 35S-incorporated alpha-CaMKII was measured by
autoradiography, and normalized to total alpha-CaMKII in the same IP (Figure 1C). A
comparison of these values in WT versus Fmr1 KO reveals that alpha-CaMKII is
excessively translated in hippocampal slices from the Fmr1 KO (WT 100 ± 12%, KO 124 ±
11%; t-test *p < 04; n = 6; Figure 1D). This increase in newly translated alpha-CaMKII is
similar in magnitude to the increase seen in total protein synthesis (Figure 1B).
We also performed the same IP experiments for glyceraldehyde phosphate dehydrogenase
(GAPDH), a non-FMRP target (Brown et al., 2001). Analysis of GAPDH levels confirmed a
significant enrichment in anti-GAPDH IPs versus IgG IPs in both WT and Fmr1 KO slices
(WT IgG 100 ± 19%, WT GAPDH 1832 ± 268%, KO IgG 99 ± 26%, KO GAPDH 2250 ±
314%; t-test WT IgG vs. GAPDH *p < 0.003, t-test KO IgG vs. GAPDH *p < 0.002; n = 5;
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Figure S2B). However, a comparison of 35S-incorporated : total ratios reveals that GAPDH
is not excessively translated in Fmr1 KO slices (WT 100 ± 9%, KO 88 ± 6%; t-test p = 0.31;
n = 5; Figure 1D). These findings suggest that the elevated total protein synthesis we detect
in the Fmr1 KO reflects de-repression of FMRP-regulated translation.
Excessive protein synthesis in the Fmr1 KO is corrected by acute, pharmacological
antagonism of mGluR5
To see whether acute pharmacological inhibition of mGluR5 could effectively reduce the
excess protein synthesis seen in juvenile Fmr1 KO hippocampus, we exposed slices to the
mGluR5 antagonist, MPEP. Interestingly, our initial experiments revealed that a 5 minute
application of 50 µM MPEP, which had no significant effect on WT protein synthesis, was
sufficient to reduce the protein synthesis in Fmr1 KO slices back to WT levels (WT control
100 ± 1%, KO control 117 ± 2%, WT MPEP 104 ± 2%, KO MPEP 95 ± 2%; ANOVA
genotype × treatment p < 0.05; n = 8; Figure 1E). Because we are particularly interested in
the protein synthesis related to mGluR-LTD, we repeated the experiment using an MPEP
treatment that has been shown to block LTD (Hou and Klann, 2004) and measured changes
in protein synthesis specifically in the CA1 region of dorsal hippocampus. Slices were pre-
incubated ± 10 µM MPEP for 30 minutes, then protein synthesis was measured for another
30 minutes ± 10 µM MPEP. Measurements restricted to microdissected area CA1 showed
that although MPEP had no effect on protein synthesis under basal conditions in WT slices,
it was sufficient to correct elevated protein synthesis in Fmr1 KO slices (WT control 100 ±
4%, KO control 117 ± 6%, WT MPEP 107 ± 7%, KO MPEP 104 ± 6%; ANOVA genotype
× treatment p < 0.02; n = 8; Figure 1F). These data represent the first demonstration that
excessive protein synthesis in the Fmr1 KO hippocampus can be rapidly corrected by acute
pharmacological inhibition of mGluR5. Thus, the elevated protein synthesis in the Fmr1 KO
is downstream of constitutive mGluR5 activation.
mGluR-mediated protein synthesis is mimicked and occluded in the Fmr1 KO
In hippocampal slices from Fmr1 KO mice, LTD induced by application of DHPG is greater
in magnitude (Huber et al., 2002) and qualitatively unlike WT because it is not reduced by
protein synthesis inhibitors (Hou et al., 2006; Nosyreva and Huber, 2006). These findings
have led to the suggestion that proteins responsible for long-term expression of LTD are
rapidly synthesized in response to mGluR activation in WT, and constitutively over-
expressed in Fmr1 KO hippocampus. Gp1 mGluR activation has been shown to lead to
increased protein synthesis in a variety of systems (Weiler and Greenough, 1993; Raymond
et al., 2000; Job and Eberwine, 2001; Todd et al., 2003; Shin et al., 2004; Muddashetty et
al., 2007). However, whether activation of mGluRs under LTD conditions leads to an
increase in protein synthesis in hippocampal slice has not been directly tested.
We observed that the same treatment that induces LTD in hippocampal slices (100 µM
DHPG, 5 min) also significantly increases protein synthesis in WT slices (Figure 1G).
Interestingly, however, the same treatment does not stimulate protein synthesis over the
elevated baseline level in Fmr1 KO hippocampal slices (WT control 100 ± 2%, WT DHPG
119 ± 2%, KO control 110 ± 5%, KO DHPG 112 ± 4%; ANOVA genotype × treatment p <
0.02; n = 8; Figure 1G). Thus, genetic deletion of FMRP appears to mimic and occlude the
effect of DHPG on protein synthesis.
No detectable difference in basal mGluR signaling under conditions of elevated protein
synthesis
Previous studies have shown that DHPG stimulation leads to activation of the MAPK/
ERK1/2 pathway (Ferraguti et al., 1999; Gallagher et al., 2004; Hou and Klann, 2004). More
recently, activation of the PI3K-Akt-mammalian target of rapamycin (mTOR) pathway has
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been reported (Hou and Klann, 2004; Sharma et al., 2010). Both pathways are linked to the
initiation of 5’ cap-dependent translation of mRNAs (Figure 2A). ERK1/2 activates the
MAPK-interacting kinase (Mnk), which leads to phosphorylation of eukaryotic initiation
factor 4E (eIF4E) (Proud, 2007). Akt facilitates the activation of mTOR, which de-represses
eIF4E by phosphorylating eIF4E binding proteins (4EBPs) (Gingras et al., 1999). mTOR
also initiates translation of 5’ TOP mRNA, which is linked to the activation of ribosomal
protein S6 kinases (i.e., p70S6K), and the subsequent phosphorylation of S6 (Proud, 2007).
Phosphorylation of both 4EBP and p70S6K are considered to be reliable and equivalent
read-outs of mTOR activation (Hara et al., 1998; Avruch et al., 2001; Wang et al., 2005).
Our results showing that the excessive protein synthesis in the Fmr1 KO hippocampus is
reversible with MPEP application suggest one of two things: (1) mGluR5 signaling is
excessive in the Fmr1 KO hippocampus, or (2) the Fmr1 KO hippocampus is hypersensitive
to normal constitutive mGluR5 signaling. In an attempt to differentiate between these two
options, we measured ERK1/2, p38 MAPK, and Akt activation in the same hippocampal
slices from WT and Fmr1 KO that had been used to measure protein synthesis. Interestingly,
we observed no basal increase in either ERK1/2 or Akt activation in Fmr1 KO slices
(ERK1/2: WT 100 ± 6%, KO 92 ± 7%; t-test p = 0.22; Akt: WT 100 ± 6%, KO 92 ± 4%; t-
test p = 0.12; n = 27; Figure 2B), despite detecting the robust increase in protein synthesis
(Figure 1B). There was, however, a small but significant decrease in phosphorylated p38 in
the Fmr1 KO (t-test *p < 0.05; n = 10; Table 1). This difference may reflect a compensatory
downregulation in response to elevated protein synthesis, but is unlikely to be a cause of the
increased protein synthesis.
To determine whether upstream or downstream effectors of these pathways were
hyperactive, we examined the phosphorylation states of PTEN, a negative regulator of the
PI3K pathway (Stambolic et al., 1998), as well as of the downstream components mTOR,
p70S6K, and S6. In all proteins tested, no significant increase in activation state was
observed in Fmr1 KO hippocampus (Table 1).
Evoked mGluR-ERK1/2 signaling appears normal in the Fmr1 KO
Results from untreated slices suggested that basal mGluR5 signaling is not excessive in the
Fmr1 KO hippocampus. However, we could not exclude the possibility that we were
missing a change that can only be seen with mGluR5 activation or in a specific biochemical
fraction. We therefore measured activation of these pathways after 5 minutes of stimulation
with 100 µM DHPG, the protocol for mGluR-LTD induction. Our results revealed that there
were no significant differences in activation of ERK1/2, p38, PTEN, Akt, mTOR, p70S6K,
or S6 between WT and Fmr1 KO (Table 2). Interestingly, while we observed a robust
activation of ERK1/2 in both WT and Fmr1 KO slices (WT control 100 ± 6%, WT DHPG
132 ± 8%, KO control 90 ± 6%, KO DHPG 135 ± 6%; ANOVA treatment p < 0.0001; n =
13; Figure 2C) we did not observe a significant activation of Akt in these slices (WT control
100 ± 5%, WT DHPG 104 ± 6%, KO control 100 ± 5%, KO DHPG 100 ± 6%; ANOVA
treatment p = 0.57; n = 14; Figure 2C). Further investigation revealed that none of the PI3K
pathway members examined (PTEN, mTOR, p70S6K and S6) were activated by DHPG in
either WT or Fmr1 KO slices (Table 2).
The exaggerated mGluR-LTD phenotype in Fmr1 KO has been described in CA1 (Huber et
al., 2002), and we wanted to confirm our results in this area of the hippocampus. Consistent
with results from whole slices, we found no hyperactivation of ERK1/2 or Akt in area CA1
microdissected from Fmr1 KO hippocampus, nor was there any occlusion of an mGluR-
stimulated response (ERK1/2: WT control 100 ± 3%, WT DHPG 164 ± 6%, KO control 79
± 7%, KO DHPG 145 ± 16%; ANOVA treatment p < 0.0001, genotype × treatment p =
0.95; n = 8; Akt: WT control 100 ± 7%, WT DHPG 106 ± 6%, KO control 95 ± 6%, KO
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DHPG 99 ± 9%; ANOVA treatment p = 0.55, genotype × treatment p = 0.89; n = 8; Figure
2D). Interestingly, a slight but significant decrease in ERK1/2 phosphorylation was seen in
Fmr1 KO CA1 suggesting the possibility of compensatory downregulation in response to
elevated protein synthesis (t-test *p < 0.008; n = 8; Figure 2D). These results support the
conclusion that ERK1/2 activation is neither elevated nor saturated in Fmr1 KO
hippocampus. Consistent with our previous results, no significant mGluR-mediated
activation of Akt was observed in either WT or Fmr1 KO CA1 (Figure 2D).
To test whether differences in mGluR-mediated signaling could be seen specifically at the
synaptic level, we measured activation of ERK1/2 and Akt in synaptoneurosome fractions
isolated from slices stimulated ± 100 µM DHPG for 5 minutes. Consistent with results from
whole slices, we find that mGluR-mediated activation of ERK1/2 is preserved in Fmr1 KO
synaptoneurosomes (WT control 100 ± 8%, WT DHPG 135 ± 8%, KO control 98 ± 10%,
KO DHPG 139 ± 9%; ANOVA treatment p < 0.0001, genotype × treatment p = 0.68; n = 10
sets of slices from 7 animals; Figure 2E). No activation of Akt was observed in either WT or
Fmr1 KO synaptoneurosomes (WT control 100 ± 9%, WT DHPG 102 ± 10%, KO control
98 ± 13%, KO DHPG 93 ± 13%; ANOVA treatment p = 0.79, genotype × treatment p =
0.60; n = 10 sets of slices from 7 animals; Figure 2E).
Our data suggest that the PI3K-Akt pathway is not basally hyperactive under conditions in
which we observe excessive protein synthesis. To ensure that our assay was sensitive to
changes in Akt activation, we exposed slices to insulin, a potent activator of the PI3K
pathway (Proud, 2007). Results from these experiments show that a 10 minute application of
1 µM insulin leads to a robust activation of Akt in both Fmr1 KO and WT slices (WT
control 100 ± 6%, WT insulin 191 ± 16%, KO control 113 ± 21%, KO insulin 205 ± 20%;
ANOVA treatment p < 0.0005, genotype × treatment p = 0.979; n = 8; Figure 2F). These
results suggest that the PI3K-Akt pathway is preserved, and not saturated, in Fmr1 KO
slices.
Taken together, the results from these experiments show that differences in basal or evoked
activation of mGluR5-mediated signaling do not parallel—and are therefore unlikely to
account for—the differences in basal and DHPG-evoked protein synthesis in Fmr1 KO
hippocampus.
Inhibition of ERK1/2, but not mTOR, corrects excessive protein synthesis in the Fmr1 KO
Our results show that the excessive protein synthesis in Fmr1 KO can be corrected by
inhibition of mGluR5, and that activation of Gp1 mGluRs leads to robust activation of
ERK1/2. We therefore hypothesized that inhibition of ERK1/2 could, like MPEP, correct the
excessive protein synthesis in the Fmr1 KO. This hypothesis was tested using the MEK1/2-
ERK1/2 inhibitor U0126, which we found robustly decreased ERK1/2 activation in WT and
Fmr1 KO at 5 µM (WT control 100 ± 15%, WT U0126 15 ± 3%; KO control 86 ± 8%, KO
U0126 12 ± 2%; ANOVA treatment p < 0.0001; n = 4; Figure 3B). Slices were pre-
incubated ± 5 µM U0126 for 30 minutes, and protein synthesis measured ± 5 µM U0126 for
an additional 30 minutes. Our results reveal that U0126 corrects protein synthesis in the
Fmr1 KO down to WT levels (WT control 100 ± 6%, KO control 115 ± 4%, WT U0126 94
± 6%; KO U0126 91 ± 6%; ANOVA genotype × treatment p < 0.03; n = 9; Figure 3B).
These results provide the first evidence that downregulation of the ERK1/2 pathway is
effective in correcting a core Fmr1 KO phenotype.
In light of a recent study proposing that the Akt/mTOR pathway contributes to the
exaggerated mGluR-LTD in the Fmr1 KO (Sharma et al., 2010), we examined whether
application of the mTOR antagonist rapamycin could rescue the excess protein synthesis in
the Fmr1 KO. Hippocampal slices were incubated ± 20 nM rapamycin for 30 minutes, then
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metabolically labeled ± 20 nM rapamycin for 30 minutes. This treatment failed to correct the
excess protein synthesis seen in the Fmr1 KO (WT control 100 ± 5%, KO control 115 ± 6%,
WT rapamycin 103 ± 3%, KO rapamycin 125 ± 8%; ANOVA genotype p < 0.002, ANOVA
genotype × treatment p = 0.51; n = 13; Figure 3C). Rapamycin was confirmed to produce
robust inhibition of mTOR by monitoring the phosphorylation of p70S6K, a direct
downstream target (WT control 100 ± 19%, WT rapamycin 24 ± 5%; KO control 94 ± 14%,
KO rapamycin 15 ± 4%; ANOVA treatment p < 0.0001, ANOVA genotype × treatment p =
0.90; n = 7; Figure 3C). These data suggest that the Akt-mTOR pathway does not contribute
directly to the excessive protein synthesis seen in the Fmr1 KO and might influence LTD by
actions other than regulation of protein synthesis.
TrkB-mediated protein synthesis is occluded in the Fmr1 KO
Results from our protein synthesis and signaling pathway experiments suggest that ERK1/2
links mGluR5 to protein synthesis, and that protein synthesis in the Fmr1 KO is
hypersensitive to the activation of this pathway (Figure 3D). This model would account for
both the selective reduction of protein synthesis in the Fmr1 KO with MPEP and U0126,
and the selective increase in protein synthesis in the WT with DHPG stimulation (Figure
3D). A prediction of this model is that synaptic protein synthesis in response to any activator
of ERK1/2 will be saturated in the Fmr1 KO hippocampus. To test this idea, we looked at
protein synthesis downstream of the BDNF receptor, TrkB, in WT and Fmr1 KO slices.
Activation of TrkB has been shown to result in ERK1/2-dependent protein synthesis at the
synapse, and this is thought to play a role in sustained LTP (Kang and Schuman, 1996;
Schratt et al., 2004; Kanhema et al., 2006).
Our goal was to test TrkB-mediated translation in our hippocampal slices; however, the
penetration of BDNF in brain slices has been shown to vary considerably depending on
experimental conditions (Kang et al., 1996). In addition, BDNF is known to activate p75-
NTR, a receptor involved in cytotoxicity (Chao, 1994). Given these limitations, we chose to
employ an antibody-based TrkB activation strategy. Dimerization of Trk receptors in
response to agonist binding leads to autophosphorylation and initiation of downstream
signaling cascades (Jing et al., 1992). Trk antibodies lead to the same activation, and have
been shown to initiate the downstream signaling and functional consequences to the same
degree as agonist application for both TrkA and TrkB (Clary et al., 1994; Qian et al., 2006).
To confirm that our monoclonal antibody activated TrkB, we applied 1 µg/ml to mature
cultured hippocampal neurons for 15 minutes. Western blotting for p-Trk Tyr490 reveals
that this treatment robustly activates TrkB, and occludes further activation via BDNF
(control 100 ± 20%, control + BDNF 553 ± 53%, TrkB 849 ± 79%, TrkB + BDNF 897 ±
14%; ANOVA, BDNF p < 0.002, TrkB p < 0.0001, BDNF × TrkB, p < 0.005; n = 4 sets of
cultures; Figure S3). Importantly, this treatment also results in strong ERK1/2 activation that
mimics and occludes activation via BDNF (control 100 ± 3%, control + BDNF 173 ± 12%,
TrkB 252 ± 20%, TrkB + BDNF 221 ± 22 %; ANOVA BDNF p = 0.187, TrkB p < 0.002,
BDNF × TrkB p < 0.02; n = 4 sets of cultures; Figure S3). We therefore used this approach
to measure TrkB-mediated translation in hippocampal slices. Slices were pre-incubated ± 1
µg/ml anti-TrkB for 30 minutes, then ActD ± 1 µg/ml anti-TrkB for another 30 minutes, and
protein synthesis measured ± 1 µg/ml anti-TrkB for 1 hour (Kelleher et al., 2004). This
treatment led to a significant increase in protein synthesis in WT slices, but failed to raise
protein synthesis over the elevated basal level in Fmr1 KO slices (WT control 100 ± 6%,
WT TrkB 132 ± 6%, KO control 121 ± 6%, KO TrkB 113 ± 9%; ANOVA genotype ×
treatment p < 0.02; n = 6; Figure 4). These results suggest that, similar to mGluR-mediated
protein synthesis, TrkB-mediated protein synthesis is occluded (and therefore dysregulated)
in the Fmr1 KO hippocampus. This finding is interesting in light of a recent study showing
that BDNF-TrkB facilitated LTP is deficient in the Fmr1 KO (Lauterborn et al., 2007). It is
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possible that the inability of TrkB to elicit further protein synthesis in the Fmr1 KO is
related to this phenotype.
Inhibition of ERK1/2 eliminates audiogenic seizures in the Fmr1 KO
If hypersensitivity to ERK1/2 pathway signaling is a core cause of pathological changes in
the Fmr1 KO, then treatment with an inhibitor of the ERK1/2 pathway might be expected to
correct other phenotypes in the Fmr1 KO. Enhanced susceptibility to audiogenic seizures
(AGS) is one of the most robust phenotypes observed in the Fmr1 KO mouse, and models
the epilepsy seen in FXS patients (Berry-Kravis, 2002; Yan et al., 2005). Acute injection of
MPEP has been shown to ameliorate the AGS phenotype in Fmr1 KO mice (Yan et al.,
2005), and we wanted to test whether acute injection a brain-penetrant MEK1/2-ERK1/2
inhibitor (SL 327), could do the same. Fmr1 KO and WT mice were injected i.p. with 100
mg/kg SL 327 (based on Zhong et al., 2009) or 50% DMSO vehicle, and returned to their
home cage for one hour. To initiate AGS, mice were transferred to a plastic test cage and
exposed to a seizure-inducing alarm for 2 minutes. During stimulus presentation, mice were
scored for four stages of AGS: wild running, clonic seizure, tonic seizure, and death (Yan et
al., 2005; Dolen et al., 2007; Zhong et al., 2009). All animals were injected and scored blind
to genotype.
Consistent with previous studies, we observed that vehicle-treated Fmr1 KO mice exhibited
a 73% incidence of AGS, in stark contrast to the 0% incidence observed in vehicle-treated
WT mice (Fisher’s exact test *p < 0.03; Table 3) (Yan et al., 2005; Dolen et al., 2007).
Strikingly, SL 327 treatment completely eliminated AGS in the Fmr1 KO, dropping the
incidence to 0% (Fisher’s exact test *p < 0.03; Table 3). These results provide the first
evidence that inhibition of ERK1/2 can correct in vivo phenotypes observed in the Fmr1
KO.
We also tested the hypothesis that rapamycin can inhibit AGS, based on recent evidence that
mTOR signaling is altered in some biochemical preparations of Fmr1 KO brain (Sharma et
al., 2010). Fmr1 KO and WT mice were injected i.p. with 6 mg/kg rapamycin (based on
Ehninger et al., 2008 and Meikle et al., 2008) or 100% DMSO vehicle, and tested for AGS
after 1 hour. Unlike the ERK inhibitor, rapamycin failed to significantly reduce the
incidence of AGS in the Fmr1 KO (Fisher’s exact test KO vehicle vs. WT vehicle *p <
0.005, KO vehicle vs. KO rapamycin p = 0.372; Table 4). Together, these results suggest
that acute inhibition of ERK1/2, but not mTOR, can correct the AGS phenotype in the Fmr1
KO.
Discussion
Although reduction of mGluR5 activity has been shown to correct multiple phenotypes in
the Fmr1 KO mouse (Aschrafi et al., 2005; Yan et al., 2005; Tucker et al., 2006; Dolen et
al., 2007; Nakamoto et al., 2007; de Vrij et al., 2008; Qiu et al., 2008), the molecular basis
has been unclear. We show here, for the first time, that acute pharmacological inhibition of
either mGluR5 or the ERK1/2 signaling pathway is sufficient to normalize protein synthesis
in Fmr1 KO hippocampus to WT levels. The elevated protein synthesis observed in the
Fmr1 KO mimics and occludes any further increases with DHPG stimulation. However,
neither basal nor stimulated activation of either the MAPK or PI3K signaling pathways were
found to be increased in the Fmr1 KO. Thus, the cause of increased protein synthesis in the
Fmr1 KO brain appears to be increased sensitivity of the protein synthetic machinery to
mGluR5-ERK1/2 signaling, rather than increased mGluR5-ERK1/2 signaling per se (Figure
5). Consistent with this model, we find that protein synthesis stimulated via another synaptic
activator of ERK1/2, the TrkB receptor, is also saturated in Fmr1 KO hippocampus.
Hypersensitivity to ERK1/2 pathway activation appears to be relevant to the disorder in vivo
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as we found that pharmacological antagonism of this pathway completely eliminates the
AGS phenotype in the Fmr1 KO.
A well-documented mechanism of translational control is the modulation of mRNA
availability to the ribosome (Richter, 2007). Given that FMRP has been estimated to bind
4% of all brain mRNAs (Ashley et al., 1993), it is possible that de-repression and “leaky”
translation of these mRNAs in response to basal ERK1/2 signaling causes the elevated
protein synthesis seen in the Fmr1 KO. Consistent with this idea, the mRNA granule
population, thought to represent translationally dormant mRNAs, is reduced in the brains of
Fmr1 KO versus WT mice (Aschrafi et al., 2005). Furthermore, acute in vivo administration
of MPEP in the Fmr1 KO animals was sufficient to shift the mRNA granule population
closer to the WT value. Considered together with the current findings, the data suggest that
mGluR5 is a major initiator of activity-regulated synaptic protein synthesis in the brain, and
that constitutive mGluR5-ERK1/2 signaling is responsible for much of the excessive protein
synthesis in the Fmr1 KO under basal conditions.
Basal protein synthesis in the WT hippocampal slice preparation was not significantly
reduced by either U0126 or rapamycin (Figure 3), but was eliminated by cycloheximide
(Figure S1). Although it is possible that increased exposure to the inhibitors might reveal
some inhibition of protein synthesis (e.g., Kelleher et al., 2004; Nie et al., 2010), the
treatments we used were sufficient to produce substantial inhibition of MEK and mTOR
enzymatic activity as assayed by reduced levels of phosphorylated ERK and p70S6K,
respectively. Thus, the data suggest that under the conditions of our experiments, basal ERK
and mTOR signaling contribute little to basal protein synthesis in the WT. The residual
protein synthesis in the presence of inhibitors is either constitutive or driven by other
signaling pathways.
Activation of mGluRs has been shown to stimulate the ERK1/2 pathway in a wide variety of
systems, including cell lines (Ferraguti et al., 1999), cultured neurons (Mao et al., 2005),
striatum (Choe and Wang, 2001), spinal cord (Adwanikar et al., 2004), hippocampal slice
(Berkeley and Levey, 2003; Gallagher et al., 2004), and retinal pigment epithelial cells
(Garcia et al., 2008). Although recent studies have shown an activation of Akt (Hou and
Klann, 2004; Sharma et al., 2010) and mTOR (Antion et al., 2008; Ronesi and Huber, 2008;
Sharma et al., 2010) in response to Gp1 mGluR activation, we did not observe this under the
conditions of our experiment. It is possible that this pathway is activated by DHPG at earlier
or later time points following stimulation than what we examined. However, the data do
indicate that this pathway is not hyperactive under basal conditions in Fmr1 KO slices that
exhibit excessive protein synthesis. Failure to observe increased activation of either ERK1/2
or Akt pathways under basal conditions is not accounted for by an insensitivity of our assay
to detect increases, as evidenced by the effects of DHPG on ERK and insulin on Akt (Figure
2).
Our findings contrast with a recent study by Sharma et al. (2010) who showed increased
Akt-mTOR pathway activation in the Fmr1 KO hippocampus, attributed by the authors to be
caused by elevated expression of the PI3K enhancer protein PIKE (Sharma et al., 2010).
One key difference between our study and theirs is the preparation of the Fmr1 KO tissue.
Our preparation was optimized to measure differences in protein metabolism in a
physiologically stable tissue slice whereas theirs was optimized to capture early postmortem
differences in protein phosphorylation. To ensure that we could replicate their findings, we
probed the status of Akt and mTOR phosphorylation in homogenates from rapidly dissected
hippocampus and similarly observed an increase in p-Akt and p-mTOR in Fmr1 KO relative
to WT (Figure S4). This difference observed in freshly dissected tissue could reflect the
status in vivo or, equally likely, a differential response to postmortem stress such as anoxia
Osterweil et al. Page 12
J Neurosci. Author manuscript; available in PMC 2012 July 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
or rapid cooling. Regardless, our results strongly suggest that elevated Akt-mTOR signaling
is not a cause of elevated protein synthesis in the Fmr1 KO (Figure 5). Firstly, we do not see
evidence for increased Akt-mTOR signaling under experimental conditions that reveal an
elevation in hippocampal protein synthesis quantitatively identical to the status in vivo (Qin
et al., 2005). Secondly, the mTOR inhibitor rapamycin does not affect the basal increase in
protein synthesis in the Fmr1 KO slices. As Sharma et al. suggest, increased activation of
the Akt-mTOR pathway could be a consequence of overexpression of the regulatory protein
PIKE. In this case, it seems more appropriate to view differences in the mTOR pathway as a
consequence rather than a cause of increased mGluR5-regulated protein synthesis in the
Fmr1 KO. That aberrant mTOR pathway activation may be distal to increased protein
synthesis in fragile X in no way diminishes the possible therapeutic significance of that
discovery. However, our finding that rapamycin treatment fails to prevent AGS (Table 4)
suggests that elevated mTOR activity may not be centrally involved in epileptogenesis
associated with FXS.
Our results showing that protein synthesis downstream of TrkB activation is saturated in the
Fmr1 KO, and that inhibition of ERK1/2 signaling can correct excessive protein synthesis,
suggest that a core defect in FXS is leaky translation in response to ERK1/2 activity.
Supporting this, we show that acute pharmacological antagonism of ERK1/2 completely
rescues the AGS phenotype in the Fmr1 mouse (Table 3). Although the major regulator of
the relevant protein synthesis activity at excitatory synapses is mGluR5, it seems likely that
other neurotransmitter systems that signal via ERK1/2 can contribute to the pathophysiology
of FXS. This insight suggests the possibility of additional therapeutic targets besides
mGluR5 for the treatment of the core pathophysiology of this disorder in humans.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Exaggerated protein synthesis in Fmr1 KO is ameliorated by mGluR5 antagonism and
mimicked by mGluR activation in WT
(A) Schematic illustrates experimental timeline: hippocampal slices were recovered in
ACSF, incubated with 25 µM ActD for 30 min, then protein synthesis was measured with 10
µCi/ml 35S-Met/Cys for 30 min. To measure the effect of post-slice recovery time on protein
synthesis, slices were incubated in ACSF for 0 h, 0.5 h, 1.5 h, 3.5 h, or 5.5 h before exposure
to ActD and metabolic labeling. Quantification of multiple experiments showed that a 4 h
post-slice recovery time yields maximal protein synthesis, which is stable for at least another
2 h (ANOVA p < 0.05; t-test: 4 h vs. 0.5 h *p < 0.04, 4 h vs. 1 h *p < 0.03, 4 h vs. 6 h p =
0.89; n = 10). (B) Protein synthesis was elevated in Fmr1 KO versus WT hippocampus (t-
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test *p < 0.02; n = 13). Differences in protein synthesis are exemplified by representative
autoradiographs and total protein stain of the same membrane. (C) Representative
immunoblots and autoradiographs show IPs for alpha-CaMKII and GAPDH from WT and
Fmr1 KO slices metabolically labeled with 50 µCi/ml 35S-Met/Cys for 1 hour. (D)
Quantification of multiple experiments reveals that the ratio of 35S-incorporated total alpha-
CaMKII is higher in Fmr1 KO slices than WT slices (t-test *p < 0.04; n = 6). In contrast, the
ratio of 35S-incorporated : total GAPDH is not elevated in Fmr1 KO versus WT slices (t-test
p = 0.31; n = 5). (E) During the first 5 minutes of metabolic labeling, WT and Fmr1 KO
slices were exposed to 50 µM MPEP or vehicle. Quantification of multiple experiments
shows that MPEP treatment corrects protein synthesis in Fmr1 KO back to WT levels (t-test
*p < 0.03; n = 8). This treatment had no significant effect on WT protein synthesis (t-test p =
0.58; n = 8). (F) WT and Fmr1 KO slices were pre-incubated ± 10 µM MPEP for 30 min,
then metabolically labeled ± 10 µM MPEP for 30 min. Measurements taken from isolated
CA1 regions show that MPEP corrects excessive protein synthesis in Fmr1 KO CA1 back to
WT levels (t-test *p < 0.02; n = 8). This treatment had no effect on WT CA1 (t-test p = 0.24;
n = 8). (G) WT and Fmr1 KO slices were stimulated ± 100 µM DHPG during the first 5
minutes of metabolic labeling. DHPG stimulation caused a robust increase in protein
synthesis in WT (t-test *p < 0.0001), but not Fmr1 KO (t-test p = 0.62), hippocampus (n =
8). N represents number of animals per group, where 1–2 slices were analyzed per animal.
Error bars represent SEM.
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Figure 2. Basal and DHPG-evoked MAPK and PI3K signaling appear normal in the Fmr1 KO
(A) Schematic shows signaling components of the PI3K and MAPK families thought to be
downstream of mGluR5 (Proud, 2007). (B) Basal activation (phosphorylation) states of
ERK1/2 and Akt were measured in untreated hippocampal slices from WT and Fmr1 KO,
the majority of which were used for the assay of basal protein synthesis. Results reveal no
difference in either ERK1/2 (t-test p = 0.223) or Akt (t-test p = 0.12) activation in Fmr1 KO
versus WT (n = 27). (C) Gp1 mGluR-mediated activation of ERK1/2 was measured
immediately after application of 100 µM DHPG for 5 min. Results reveal that DHPG
significantly increases ERK1/2 activation in both WT (t-test *p < 0.0001) and Fmr1 KO (t-
test *p < 0.0001) slices (n = 14). Interestingly, activation of Akt was not observed in either
WT (t-test p = 0.47) or Fmr1 KO (t-test p = 0.96) slices (n = 14). (D) ERK1/2 and Akt
activation was measured in microdissected CA1 after 5 min application of 100 µM DHPG.
Analyses reveal that stimulation of Gp1 mGluRs leads to a significant activation of ERK1/2
in both WT (t-test *p < 0.0001) and Fmr1 KO (t-test *p < 0.006) CA1 (n = 8). A slight but
significant reduction in basal ERK1/2 activation is seen in Fmr1 KO CA1 (t-test *p <
0.008). Basal activation of Akt in Fmr1 KO CA1 is not significantly different from WT CA1
(t-test p = 0.65), and no activation of Akt is observed in either WT (t-test p = 0.61) or Fmr1
KO (t-test p = 0.76) CA1 (n = 8). (E) Synaptoneurosomes were isolated from sets of slices
treated with 100 µM DHPG for 5 min, and levels of ERK1/2 and Akt activation were
assessed. Results reveal a significant activation of ERK1/2 in both WT (t-test *p < 0.001)
and Fmr1 KO (t-test *p < 0.01) synaptoneurosomes (n = 10 sets of slices from 7 animals).
No activation of Akt was observed in either WT (t-test p = 0.88) or Fmr1 KO (t-test p =
0.47) synaptoneurosomes (n = 10 sets of slices from 7 animals). (F) Activation of Akt was
measured after a 10 min application of 1 µM insulin. Results reveal a robust activation of
Akt in both WT (t-test *p < 0.001) and Fmr1 KO (t-test *p < 0.05) slices (n = 8).
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Representative immunoblots reflect quantified results. Unless otherwise noted, n represents
number of animals per group, where 1–2 slices were analyzed per animal. Error bars
represent SEM.
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Figure 3. Inhibition of ERK1/2, but not mTOR, corrects excessive protein synthesis in the Fmr1
KO
(A) Schematic illustrates experimental timeline: WT and Fmr1 KO hippocampal slices are
recovered, incubated with 25 µM ActD ± inhibitor for 30 min, then protein synthesis
measured ± inhibitor for 30 min. (B) Protein synthesis and ERK1/2 activation were
measured in slices incubated ± 5 µM U0126. Exposure to 5 µM U0126 significantly reduces
protein synthesis in Fmr1 KO (t-test *p < 0.006), but not WT (t-test p = 0.15) slices (n = 9).
This concentration of U0126 significantly reduced ERK1/2 activation in both WT (t-test *p
< 0.01) and Fmr1 KO (t-test *p < 0.005) slices (n = 4). (C) Protein synthesis and p70S6K
activation were measured in slices incubated ± 20 nM rapamycin. Exposure to 20 nM
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rapamycin does not correct protein synthesis in the Fmr1 KO (WT control vs. KO control t-
test *p < 0.03; WT rapamycin vs. KO rapamycin t-test *p < 0.02; n = 13). This dose of
rapamycin robustly reduces p70S6K activation in both WT (t-test *p < 0.02) and Fmr1 KO
(t-test *p < 0.002) slices (n = 7). Quantified changes are shown in representative
immunoblots. N represents number of animals per group, where 1–2 slices were analyzed
per animal. Error bars represent SEM. (D) Our results suggest the illustrated model of the
relationship between mGluR5-mediated ERK1/2 activation and synaptic protein synthesis in
WT and Fmr1 KO. In Fmr1 KO, the loss of FMRP renders the activation of protein
synthesis the more sensitive to basal levels of mGluR5-ERK1/2 activity. Inhibition of basal
mGluR5-ERK1/2 with MPEP or U0126 leads to a significant decrease in Fmr1 KO, but not
WT protein synthesis due to this hypersensitivity. Conversely, DHPG does not elevate of
protein synthesis in Fmr1 KO because mGluR5-ERK1/2-mediated protein synthesis is
already saturated.
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Figure 4. TrkB-mediated protein synthesis is mimicked and occluded in the Fmr1 KO
WT and Fmr1 KO hippocampal slices were recovered, pre-incubated ±1 µg/ml anti-TrkB for
30 min, then 25 µM ActD ±1 µg/ml anti-TrkB for an additional 30 min, and 1 h of protein
synthesis measured ±1 µg/ml anti-TrkB. Results show that TrkB activation leads to a
significant increase in protein synthesis in WT (t-test *p < 0.03) but not Fmr1 KO (t-test p =
0.433) slices (n = 6). Schematic illustrates the time course of the experiment. Quantified
differences are exemplified by representative autoradiograph and total protein stain of the
same membrane. N represents number of animals per group, where 1–2 slices were analyzed
per animal. Error bars represent SEM.
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Figure 5. Heuristic models of the interaction between mGluR5 and FMRP
Illustrated are simple logical relationships between FMRP and mGluR5-stimulated synaptic
protein synthesis. (A) The finding of elevated protein synthesis downstream of constitutive
mGluR5 activation suggested a model in which FMRP or an FMRP-regulated protein
specifically inhibits the signaling pathway that couples mGluR5 to translation initiation
(Hou et al., 2006; Sharma et al., 2010). (B) An alternative to the model in which signaling is
unaffected in the absence of FMRP, but the consequences on protein synthesis are
exaggerated. The results of the current investigation favor model B.
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Table 1
No basal upregulation of MAPK or PI3K pathways in the Fmr1 KO
Basal activation (phosphorylation) states of ERK1/2, p38, and the PI3K pathway proteins PTEN, Akt, mTOR,
p70S6K and S6 were measured untreated hippocampal slices from Fmr1 KO and WT, the majority of which
were used for measurement of protein synthesis. Results are expressed as % average WT ± SEM. For all
proteins, no significant increase was seen in Fmr1 KO as compared to WT. In contrast, a small but significant
decrease in the activation state of p38 (t-test *p < 0.05) was observed in Fmr1 KO. For each animal, 1–2 slices
were analyzed. ERK1/2 and Akt data are graphically represented in Figure 2.
Protein Phosphorylation site Phospho / total Animals
WT KO
Erk1/2 Thr202/Tyr204 100 ± 6 % 92 ± 7 % 27
Akt Ser473 100 ± 6 % 92 ± 4 % 27
p38 * Thr180/Tyr182 100 ± 8 % 85 ± 7 % 10
PTEN Ser380/Thr382/383 100 ± 13 % 100 ± 11 % 10
mTOR Ser2448 100 ± 7 % 111 ± 8 % 16
p70S6K Thr389 100 ± 8 % 102 ± 6 % 19
S6 Ser235/236 100 ± 12 % 79 ± 7 % 17
T-test *p < 0.05
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